Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14350MR)

This product GTTS-WQ14350MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14350MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15211MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ10229MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ7696MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ3867MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ9985MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ12953MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ8880MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ7820MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK 716155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW